• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗体对 SARS-CoV-2 的反应揭示了非结构/辅助蛋白和结构蛋白之间的显著差异。

Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins.

机构信息

Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.

Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China; Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.

出版信息

Cell Rep. 2021 Jul 13;36(2):109391. doi: 10.1016/j.celrep.2021.109391. Epub 2021 Jun 26.

DOI:10.1016/j.celrep.2021.109391
PMID:34242574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8233850/
Abstract

The immunogenicity of the SARS-CoV-2 proteome is largely unknown, especially for non-structural proteins and accessory proteins. In this study, we collect 2,360 COVID-19 sera and 601 control sera. We analyze these sera on a protein microarray with 20 proteins of SARS-CoV-2, building an antibody response landscape for immunoglobulin (Ig)G and IgM. Non-structural proteins and accessory proteins NSP1, NSP7, NSP8, RdRp, ORF3b, and ORF9b elicit prevalent IgG responses. The IgG patterns and dynamics of non-structural/accessory proteins are different from those of the S and N proteins. The IgG responses against these six proteins are associated with disease severity and clinical outcome, and they decline sharply about 20 days after symptom onset. In non-survivors, a sharp decrease of IgG antibodies against S1 and N proteins before death is observed. The global antibody responses to non-structural/accessory proteins revealed here may facilitate a deeper understanding of SARS-CoV-2 immunology.

摘要

SARS-CoV-2 蛋白组的免疫原性在很大程度上是未知的,特别是对于非结构蛋白和辅助蛋白。在这项研究中,我们收集了 2360 份 COVID-19 血清和 601 份对照血清。我们在含有 20 种 SARS-CoV-2 蛋白的蛋白质微阵列上分析这些血清,构建针对 IgG 和 IgM 的抗体反应图谱。非结构蛋白和辅助蛋白 NSP1、NSP7、NSP8、RdRp、ORF3b 和 ORF9b 引起普遍的 IgG 反应。非结构/辅助蛋白的 IgG 模式和动态与 S 和 N 蛋白不同。针对这六种蛋白的 IgG 反应与疾病严重程度和临床结局相关,并且在症状出现后约 20 天急剧下降。在非幸存者中,在死亡前观察到针对 S1 和 N 蛋白的 IgG 抗体急剧下降。这里揭示的针对非结构/辅助蛋白的全球抗体反应可能有助于更深入地了解 SARS-CoV-2 免疫学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/8a51b632fef1/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/e832721ca9ef/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/98adb981ac48/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/423c3a981d1c/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/d15657a387ea/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/f4fd5b369fbc/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/8a51b632fef1/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/e832721ca9ef/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/98adb981ac48/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/423c3a981d1c/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/d15657a387ea/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/f4fd5b369fbc/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fde/8233850/8a51b632fef1/gr5_lrg.jpg

相似文献

1
Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins.抗体对 SARS-CoV-2 的反应揭示了非结构/辅助蛋白和结构蛋白之间的显著差异。
Cell Rep. 2021 Jul 13;36(2):109391. doi: 10.1016/j.celrep.2021.109391. Epub 2021 Jun 26.
2
Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients.动态描绘体液免疫对 SARS-CoV-2 的反应图谱,鉴定与重症 COVID-19 患者存活相关的非结构蛋白抗体。
Signal Transduct Target Ther. 2021 Aug 17;6(1):304. doi: 10.1038/s41392-021-00718-w.
3
SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses.SARS-CoV-2 蛋白组微阵列用于全面分析 COVID-19 特异性 IgG 和 IgM 反应。
Nat Commun. 2020 Jul 14;11(1):3581. doi: 10.1038/s41467-020-17488-8.
4
Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.采用微阵列和其他 12 种免疫分析法评估急性 SARS-CoV-2 感染中 S1、S2 和 NCP 特异性 IgM、IgA 和 IgG 抗体的动力学。
J Clin Microbiol. 2021 Apr 20;59(5). doi: 10.1128/JCM.02890-20.
5
SARS-CoV-2-specific antibody response characteristics in COVID-19 patients of different ages.不同年龄段 COVID-19 患者的 SARS-CoV-2 特异性抗体反应特征。
Acta Biochim Biophys Sin (Shanghai). 2022 Apr 25;54(4):556-564. doi: 10.3724/abbs.2022014.
6
SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?SARS-CoV-2 蛋白:它们是否可作为 COVID-19 药物和疫苗的靶点?
Curr Mol Med. 2022;22(1):50-66. doi: 10.2174/1566524021666210223143243.
7
Anti-SARS-CoV-2 IgG responses are powerful predicting signatures for the outcome of COVID-19 patients.抗 SARS-CoV-2 IgG 反应是 COVID-19 患者结局的有力预测标志物。
J Adv Res. 2021 Nov 26;36:133-145. doi: 10.1016/j.jare.2021.11.014. eCollection 2022 Feb.
8
Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.SARS-CoV-2 感染和 COVID-19 康复过程中抗 SARS-CoV-2 抗体的动态变化。
Nat Commun. 2020 Nov 27;11(1):6044. doi: 10.1038/s41467-020-19943-y.
9
Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.日本一种新型自动化化学发光抗SARS-CoV-2 IgM和IgG抗体检测系统的验证,该系统可同时检测N蛋白和S蛋白。
PLoS One. 2021 Mar 4;16(3):e0247711. doi: 10.1371/journal.pone.0247711. eCollection 2021.
10
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19.SARS-CoV-2 感染会在有症状的 COVID-19 康复患者中诱导出持续的体液免疫反应。
Nat Commun. 2021 Mar 22;12(1):1813. doi: 10.1038/s41467-021-22034-1.

引用本文的文献

1
Dynamics of spike-specific neutralizing antibodies across five-year emerging SARS-CoV-2 variants of concern reveal conserved epitopes that protect against severe COVID-19.五年间新冠病毒变异株中刺突蛋白特异性中和抗体的动态变化揭示了可预防重症新冠的保守表位。
Front Immunol. 2025 Feb 18;16:1503954. doi: 10.3389/fimmu.2025.1503954. eCollection 2025.
2
Evolution of SARS-CoV-2 in white-tailed deer in Pennsylvania 2021-2024.2021 - 2024年宾夕法尼亚州白尾鹿体内新冠病毒的演变
PLoS Pathog. 2025 Jan 24;21(1):e1012883. doi: 10.1371/journal.ppat.1012883. eCollection 2025 Jan.
3
The role of inflammatory gene polymorphisms in severe COVID-19: a review.

本文引用的文献

1
SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution.用于在氨基酸分辨率下绘制新冠病毒抗体相互作用图谱的严重急性呼吸综合征冠状病毒2蛋白质组芯片
ACS Cent Sci. 2020 Dec 23;6(12):2238-2249. doi: 10.1021/acscentsci.0c00742. Epub 2020 Oct 21.
2
Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections.无症状 COVID-19 感染者体内针对 SARS-CoV-2 的抗体动态变化。
Allergy. 2021 Feb;76(2):551-561. doi: 10.1111/all.14622. Epub 2020 Oct 26.
3
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.
炎症基因多态性在重症新型冠状病毒肺炎中的作用:综述
Virol J. 2024 Dec 20;21(1):327. doi: 10.1186/s12985-024-02597-3.
4
Dynamics of Spike-Specific Neutralizing Antibodies Across Five-Year Emerging SARS-CoV-2 Variants of Concern Reveal Conserved Epitopes that Protect Against Severe COVID-19.跨越五年的新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)关注变异株中刺突蛋白特异性中和抗体的动态变化揭示了可预防重症冠状病毒病2019(COVID-19)的保守表位
bioRxiv. 2024 Sep 25:2024.09.22.614369. doi: 10.1101/2024.09.22.614369.
5
Intracellular delivery strategies using membrane-interacting peptides and proteins.利用膜相互作用肽和蛋白质的细胞内递药策略。
Nanoscale. 2024 Aug 22;16(33):15465-15480. doi: 10.1039/d4nr02093f.
6
Characterization of humoral immune responses against SARS-CoV-2 accessory proteins in infected patients and mouse model.鉴定感染患者和小鼠模型中针对 SARS-CoV-2 辅助蛋白的体液免疫反应。
Virol Sin. 2024 Jun;39(3):414-421. doi: 10.1016/j.virs.2024.04.005. Epub 2024 Apr 26.
7
Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy.通过高内涵显微镜技术将严重急性呼吸综合征冠状病毒2(SARS-CoV-2)膜蛋白特异性抗体确立为有价值的血清学靶点。
iScience. 2023 Jul 21;26(7):107056. doi: 10.1016/j.isci.2023.107056. Epub 2023 Jun 7.
8
Immunology of SARS-CoV-2 infection and vaccination.SARS-CoV-2 感染和疫苗接种的免疫学。
Clin Chim Acta. 2023 May 1;545:117390. doi: 10.1016/j.cca.2023.117390. Epub 2023 May 13.
9
Validation of N Protein Antibodies to Diagnose Previous SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers: Use of Roche Elecsys Immunoassay in the S Protein Vaccination Era.验证 N 蛋白抗体用于诊断大批次医护人员既往 SARS-CoV-2 感染:罗氏 Elecsys 免疫分析法在 S 蛋白疫苗接种时代的应用。
Viruses. 2023 Apr 7;15(4):930. doi: 10.3390/v15040930.
10
Can T Cells Abort SARS-CoV-2 and Other Viral Infections?T 细胞能否终止 SARS-CoV-2 及其他病毒感染?
Int J Mol Sci. 2023 Feb 22;24(5):4371. doi: 10.3390/ijms24054371.
对 COVID-19 患者的病毒表位分析揭示了交叉反应性和严重程度的相关性。
Science. 2020 Nov 27;370(6520). doi: 10.1126/science.abd4250. Epub 2020 Sep 29.
4
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant.SARS-CoV-2 ORF3b 是一种有效的干扰素拮抗剂,其活性可被一种自然发生的延长变异体增强。
Cell Rep. 2020 Sep 22;32(12):108185. doi: 10.1016/j.celrep.2020.108185. Epub 2020 Sep 4.
5
The coding capacity of SARS-CoV-2.SARS-CoV-2 的编码能力。
Nature. 2021 Jan;589(7840):125-130. doi: 10.1038/s41586-020-2739-1. Epub 2020 Sep 9.
6
Humoral Immune Response to SARS-CoV-2 in Iceland.冰岛人针对 SARS-CoV-2 的体液免疫反应。
N Engl J Med. 2020 Oct 29;383(18):1724-1734. doi: 10.1056/NEJMoa2026116. Epub 2020 Sep 1.
7
Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis.病毒-宿主相互作用组和蛋白质组学调查揭示了影响 SARS-CoV-2 发病机制的潜在毒力因子。
Med. 2021 Jan 15;2(1):99-112.e7. doi: 10.1016/j.medj.2020.07.002. Epub 2020 Jul 21.
8
ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection.ORF8 和 ORF3b 抗体是 SARS-CoV-2 早期和晚期感染的准确血清学标志物。
Nat Immunol. 2020 Oct;21(10):1293-1301. doi: 10.1038/s41590-020-0773-7. Epub 2020 Aug 17.
9
SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70.严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)的Orf9b蛋白通过靶向TOM70抑制I型干扰素反应。
Cell Mol Immunol. 2020 Sep;17(9):998-1000. doi: 10.1038/s41423-020-0514-8. Epub 2020 Jul 29.
10
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.轻度新冠肺炎患者体内抗SARS-CoV-2抗体的快速衰减
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.